Summary statistics of characteristics of samples used in the study
Variable | OC1 (Training set) | OC2 (Test set) |
---|---|---|
Total sample size, N | 91 | 208 |
Healthy controls, n (%) | 48 (52.7%) | 52 (25%) |
LMP, n (%) | 0 | 52 (25%) |
Cancer cases, n (%) | 43 (47.3%) | 104 (50%) |
By stage, n (%) | ||
I | 0 | 34 (32.7%) |
II | 0 | 18 (17.3%) |
III | 34 (79.1%) | 47 (45.2%) |
IV | 9 (2.1%) | 5 (4.8%) |
By histology subtype, n (%) | ||
High-grade serous adenocarcinoma, including papillary types | 43 (100%) | 66 (63.5%) |
Endometrioid adenocarcinoma | — | 21 (20.2%) |
Clear cell adenocarcinoma | — | 10 (9.6%) |
Epithelial adenocarcinoma, not otherwise specified | — | 7 (6.7%) |
Agea, mean ± SD | 52.44 ± 6.73 | 52.75 ± 5.84 |
CA125a, mean ± SD | 261.64 ± 542.71 | 211.35 ± 425.85 |
By disease category, mean ± SD | ||
Healthy control | 17.26 ± 11.79 | 19.33 ± 3.95 |
LMP | — | 119.47 ± 217.01 |
EOC stage I—II | — | 242.82 ± 428.66 |
EOC stage III—IV | 541.78 ± 699.88 | 463.77 ± 626.93 |
↵aAge and CA125 level did not significantly differ between the OC1 and OC2 sets at the 0.05 significance level.